FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Public ClinicalTrials.gov record NCT01226719. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection, in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
In this Phase II study the investigators plan to determine the overall response rate (ORR) of the combination of FOLFOXIRI plus panitumumab as first-line treatment of patients with liver-only metastatic KRAS wild-type colorectal cancer.
Study identification
- NCT ID
- NCT01226719
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 15 participants
Conditions and interventions
Conditions
Interventions
- Panitumumab Drug
- Oxaliplatin Drug
- Irinotecan Drug
- Leucovorin Drug
- 5-Fluorouracil Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2010 (Type not available)
- Primary completion
- Mar 2014 (Actual)
- Completion
- Mar 2014 (Actual)
- Last update posted
- May 27, 2015
2010 – 2014
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| NEA Baptist Clinic | Jonesboro | Arkansas | 72401 | — |
| Florida Cancer Specialists | Fort Myers | Florida | 33916 | — |
| Florida Hospital Cancer Institute | Orlando | Florida | 32804 | — |
| Florida Cancer Specialists | St. Petersburg | Florida | 33705 | — |
| Northeast Georgia Medical Center | Gainesville | Georgia | 30501 | — |
| Hope Cancer Center | Terre Haute | Indiana | 47802 | — |
| Providence Medical Group | Terre Haute | Indiana | 47802 | — |
| Center for Cancer and Blood Disorders | Bethesda | Maryland | 20817 | — |
| Portsmouth Regional Hospital | Portsmouth | New Hampshire | 03801 | — |
| Hematology-Oncology Associates of Northern NJ | Morristown | New Jersey | 07960 | — |
| Oncology Hematology Care, Inc | Cincinnati | Ohio | 45242 | — |
| Chattanooga Oncology Hematology Associates | Chattanooga | Tennessee | 37404 | — |
| Family Cancer Center | Collierville | Tennessee | 38017 | — |
| Tennessee Oncology, PLLC | Nashville | Tennessee | 37203 | — |
| The Center for Cancer and Blood Disorders | Fort Worth | Texas | 76104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01226719, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 27, 2015 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01226719 live on ClinicalTrials.gov.